Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Up 25.1% in December

Bionano Genomics, Inc. (NASDAQ:BNGO) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 15,840,000 shares, a growth of 25.1% from the November 30th total of 12,660,000 shares. Currently, 15.6% of the shares of the company are sold short. Based on an average daily trading volume, of 2,880,000 shares, the short-interest ratio is presently 5.5 days.

Bionano Genomics Price Performance

Bionano Genomics stock traded down $0.01 during midday trading on Friday, hitting $0.21. 3,283,279 shares of the company’s stock were exchanged, compared to its average volume of 1,925,167. The stock has a 50-day moving average price of $0.25 and a two-hundred day moving average price of $0.43. Bionano Genomics has a 52-week low of $0.19 and a 52-week high of $2.27. The company has a market cap of $21.42 million, a P/E ratio of -0.09 and a beta of 2.28. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BNGO. Armistice Capital LLC purchased a new position in Bionano Genomics in the second quarter worth $1,138,000. Geode Capital Management LLC lifted its stake in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after purchasing an additional 283,639 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Bionano Genomics in the 3rd quarter worth about $46,000. Finally, Carret Asset Management LLC boosted its holdings in shares of Bionano Genomics by 89.0% in the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after purchasing an additional 40,055 shares in the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BNGO shares. BTIG Research lowered Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th. LADENBURG THALM/SH SH cut Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.